LXRX News Alert Lexicon Pharmaceuticals (LXRX) 0.90 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lexicon Pharmaceuticals (LXRX) 0.90 $LXRX

Lexicon (LXRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:48AM CST
Lexicon has been witnessing a positive trend in its current year loss estimates and possess a favorable Zacks Industry Rank
LXRX: 0.90 (+0.02)

Lexicon Pharmaceuticals (LXRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:01AM CST
Lexicon Pharmaceuticals is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
LXRX: 0.90 (+0.02)

Lexicon To Present At The Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Mon Dec 08, 5:02PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 4:30 PM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 0.90 (+0.02)

Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.70 (+0.01), LXRX: 0.90 (+0.02), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), MNTA: 11.42 (-0.06)

Lexicon concludes USD280m in concurrent financing transactions
M2 - Fri Nov 28, 3:01AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) disclosed on Thursday the completion of the concurrent transactions for gross proceeds of USD280.0m.
LXRX: 0.90 (+0.02)

InsiderInsights.com Daily Round Up 11/26/14: VRX, INTX, AEHR, HRG
InsiderInsights - at Seeking Alpha - Wed Nov 26, 11:53PM CST

SC: 20.09 (-0.19), VRX: 140.33 (-0.22), LXRX: 0.90 (+0.02), NEOT: 6.65 (+0.25), AEHR: 2.80 (+0.11), BBY: 38.89 (-0.80), SGM: 12.35 (+0.05), FIVE: 38.76 (-0.11), INTX: 3.83 (-0.03), SPW: 86.64 (-0.11), REXX: 5.17 (-0.17), HRG: 13.98 (-0.02), PF: 35.32 (+0.13), PGRE: 18.46 (-0.07), AAPL: 112.01 (-0.53), INTU: 94.59 (-0.56), CSCO: 28.30 (+0.05), KPTI: 37.78 (+1.28)

Lexicon Announces Completion Of $280 Million In Financing Transactions
PR Newswire - Wed Nov 26, 3:01PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of previously announced concurrent financing transactions resulting in gross proceeds of $280.0 million. After fees and estimated offering expenses, Lexicon anticipates net proceeds of approximately $273.7 million from the transactions. The transactions consisted of:
LXRX: 0.90 (+0.02)

A Change In Strategy: Lexicon Pharmaceuticals
Samuel Riehn - at Seeking Alpha - Sun Nov 23, 11:04PM CST

LXRX: 0.90 (+0.02)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 11:46AM CST

LEJU: 10.72 (+0.28), GEOS: 26.42 (-0.61), LXRX: 0.90 (+0.02), OTIV: 1.71 (unch), GME: 33.39 (-1.24), ARUN: 18.45 (+0.40), NBS: 3.27 (+0.02), PHMD: 1.46 (-0.03), AMDA: 0.64 (-0.01), CANF: 3.70 (+0.01), MOLG: 2.92 (+0.03), WAIR: 14.20 (unch), EDAP: 1.97 (+0.01), FWM: 2.80 (-0.03), GERN: 3.06 (+0.05), OCRX: 5.77 (+0.02), NGVC: 26.39 (+0.09), SFUN: 7.17 (-0.03), EJ: 7.48 (+0.17), BGI: 1.66 (+0.20)

Lexicon Pharmaceuticals Fights On
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 21, 11:09AM CST

LXRX: 0.90 (+0.02)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:13AM CST

NETE: 1.20 (unch), ANV: 0.88 (+0.02), EXXI: 3.45 (-0.22), LXRX: 0.90 (+0.02), OTIV: 1.71 (unch), GME: 33.39 (-1.24), ARUN: 18.45 (+0.40), GFI: 4.37 (+0.13), CLF: 6.06 (-0.09), NYMT: 7.71 (-0.06), AMDA: 0.64 (-0.01), MOLG: 2.92 (+0.03), SID: 2.24 (-0.08), SCTY: 56.76 (+0.92), VALE: 8.09 (-0.05), SFUN: 7.17 (-0.03), GOL: 5.16 (-0.04), SPLK: 61.49 (-0.11), ICLD: 3.00 (-0.02), BBL: 42.86 (-0.19), ROST: 92.72 (-0.60)

How To Be Smarter About Risk Management
Morningstar - Seeking Alpha - Fri Nov 21, 7:00AM CST
By Alex Bryan Note: This article is part of Morningstar's November 2014 Risk Management Week special report. An earlier version appeared Aug. 13, 2014. In isolation, risk is neither good nor bad. Finance 101 teaches that the market must offer...
MMM: 166.96 (+0.09), SPY: 207.77 (+0.02), SPLV: 38.47 (+0.06), LXRX: 0.90 (+0.02), QUAL: 62.88 (-0.12), USMV: 40.99 (-0.19)

Lexicon prices public offering at USD1.005 per share
M2 - Fri Nov 21, 6:05AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) said on Thursday that it has priced a public offering of USD50m shares of its common stock.
LXRX: 0.90 (+0.02)

Lexicon Announces Pricing Of Convertible Senior Notes Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has priced its offering of $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the "Convertible Notes" in a private offering within the United States. The Convertible Notes were offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . Lexicon has also granted the initial purchasers an option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes on the same terms and conditions, solely to cover over-allotments. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.
LXRX: 0.90 (+0.02)

Lexicon Announces Pricing Of Common Stock Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement. The offering will consist of 49,751,244 shares of common stock at a public offering price of $1.005 per share. Lexicon has also granted the underwriters a 30-day option to purchase up to 7,462,687 additional shares of common stock. All of the shares in the offering will be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. are acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.
JPM: 62.48 (unch), LXRX: 0.90 (+0.02)

Lexicon drops on dilutive stock offering
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 11:35AM CST

LXRX: 0.90 (+0.02)

Stock to Watch: Lexicon Pharmaceuticals Down 17.0% (LXRX)
Comtex SmarTrend(R) - Thu Nov 20, 10:08AM CST
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's worst performing low-priced stocks, down 17.0% to $1.04 on 3.9x average daily volume. Thus far today, Lexicon Pharmaceuticals has traded 4.0 million shares, vs. average volume of 1.0 million shares per day. The stock has underperformed the Dow (-17.0% to the Dow's -0.0%) and underperformed the S&P 500 (-17.0% to the S&P's 0.1%) during today's trading.
LXRX: 0.90 (+0.02)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 8:15AM CST

GPRO: 66.41 (+4.87), ANV: 0.88 (+0.02), WD: 17.63 (+0.28), LXRX: 0.90 (+0.02), JMEI: 15.09 (+0.21), LOCO: 21.07 (+0.39), MAGS: 5.48 (+0.29), WSM: 75.32 (-0.61), CZR: 15.44 (+0.20), ITUB: 13.10 (+0.21), MBLY: 44.00 (+0.05)

Lexicon Pharma to sell USD50m common stock in public offering
M2 - Thu Nov 20, 5:34AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) said on Wednesday that it plans to sell USD50m shares of its common stock in a public offering.
LXRX: 0.90 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 113

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 86

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 426

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 133

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 73

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading

Top 5 Most Recently Viewed Articles

RPM International Reports Strong Sales Amid Tariff Challenges

Updated Category News Views 147

RPM International Achieves Notable Sales Growth RPM International Inc. (NYSE: RPM) has recently announced a significant financial performance, showcasing record sales during its first fiscal quarter. The company reported an impressive $2.11 billion in sales, marking a 7.4% increase from $1.97 billion in the same quarter of the previous year, surpassing estimates of $2.057...

Continue Reading
Growing CRM Market Driven by AI: Insights for 2024-2028

Updated Category News Views 122

CRM Market Shift: Embracing AI and SME Adoption The global CRM market is experiencing significant growth, projected to increase by USD 60 billion between 2024 and 2028. This robust expansion reflects a compound annual growth rate (CAGR) of 10.23%. A major contributor to this trend is the growing acceptance of customer relationship management (CRM) systems among small and...

Continue Reading
Rexel Announces Key Changes in Executive Leadership Team

Updated Category News Views 586

Leadership Appointments at Rexel Rexel, a leader in the multichannel distribution of energy solutions, has recently made significant appointments to its Group Executive Committee. These changes signify the company's commitment to innovation and strategies that drive transformation in their markets. New Responsibilities and Key Appointments A notable change is the...

Continue Reading
Strike Performance Footwear: Innovation for Passionate Anglers

Updated Category News Views 141

Revolutionizing Angling Footwear with Strike The world of fishing is about to be transformed with the introduction of Strike, a performance footwear brand designed by anglers, for anglers. This innovative brand stands out for its commitment to sustainability without compromising on comfort and performance. Whether you are on the water, on deck, or by the shore, Strike...

Continue Reading
Ascentage Pharma Plans 2025 Mid-Year Results Release and Update

Updated Category News Views 216

Ascentage Pharma to Release 2025 Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) is on the verge of a significant update for stakeholders and investors. The company, recognized for its commitment to addressing unmet needs in cancer treatment, has announced plans to unveil their unaudited interim results for the first six months of 2025....

Continue Reading